Advancing Safe Medications for Moms and Babies Act of 2026
HB8651, titled the Advancing Safe Medications for Moms and Babies Act of 2026, is a federal health research bill aimed at increasing the inclusion of pregnant and lactating women in clinical research. It directs the Secretary of Health and Human Services, through FDA, to harmonize FDA human-subject protection regulations with HHS rules governing the inclusion of pregnant women in research, and requires those regulations to be finalized within 180 days of enactment.
The bill also creates a public education campaign to inform patients, families, providers, and other audiences about the benefits of including pregnant and lactating women in research, available trials and registries, and how to enroll. In addition, it directs NIH, through NICHD, to establish a research prioritization process and fund priority projects on existing and new drugs used by pregnant and lactating women, with consultation from medical societies, women’s health organizations, and groups representing communities with high maternal mortality and morbidity. The bill includes reporting, public comment, and oversight requirements, and authorizes funding for both the education campaign and the research program for fiscal years 2027 through 2031.
If enacted, the bill would affect federal regulations and agency practice rather than state law, primarily by requiring FDA and HHS to align their research-subject protections and by expanding NIH/NICHD research activity focused on pregnancy and lactation. It would likely increase the number of clinical trials, registries, educational materials, and federally prioritized studies involving pregnant and lactating women, while also creating new administrative duties, deadlines, and reporting obligations for HHS, FDA, and NIH. The bill authorizes appropriations of $5 million annually for the education campaign and such sums as necessary for the research program.
The available context suggests a generally supportive and bipartisan posture toward the bill, as reflected by its introduction by members from both parties and its health-focused framing around maternal and infant safety. No committee transcripts or votes are provided, so there is no recorded floor or committee debate to indicate formal opposition or amendment activity. Overall, the bill appears to be presented as a public health and research modernization measure rather than a partisan policy dispute.
The main potential points of contention are likely to be the scope of FDA/HHS regulatory harmonization, the extent to which pregnant women should be included in clinical trials given safety and liability concerns, and the level of federal spending and NIH prioritization authority. Stakeholders concerned with research ethics may focus on protections for pregnant participants, while advocates for maternal health are likely to support broader inclusion because of gaps in evidence for drugs used during pregnancy and lactation. Medical societies, industry representatives, and women’s health organizations are explicitly invited into the process, suggesting the bill anticipates technical rather than ideological disagreement.